Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
801 JPY | +0.12% | -0.62% | -31.66% |
04-25 | JCR Pharmaceuticals Co., Ltd. Announces Management Changes, Effective as of June 26, 2024 | CI |
03-21 | US Fed Rate Outlook Catapults Japanese Shares to Fresh 52-Week Peak | MT |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The company returns high margins, thereby supporting business profitability.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Analyst opinion has improved significantly over the past four months.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Over the past twelve months, analysts' opinions have been revised negatively.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-31.66% | 651M | - | ||
+32.95% | 700B | C+ | ||
+26.51% | 569B | B | ||
-4.97% | 358B | C+ | ||
+18.83% | 330B | B- | ||
+3.54% | 287B | C+ | ||
+15.70% | 236B | B+ | ||
+6.68% | 202B | B- | ||
-9.08% | 197B | A+ | ||
+6.70% | 161B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 4552 Stock
- Ratings JCR Pharmaceuticals Co., Ltd.